A U.S. Post-Approval Study of the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Aspirin; Clopidogrel; Prasugrel; Ticagrelor; Ticlopidine
Indications Coronary disorders; Coronary stent thrombosis; Myocardial ischaemia
Focus Therapeutic Use
Acronyms PE Plus PAS
Sponsors Boston Scientific Corporation

23 Feb 2021 Results (n=4184) of pooled analysis of two studies (Platinum Diversity (PD) and Promus Element Plus (PE Plus)), published in the American Heart Journal.
11 Mar 2019 Primary endpoint has been met. (Cardiac Death or Myocardial Infarction Rate in PLATINUM-like Patients)
11 Mar 2019 Results evaluating the safety and performance of a platinum chromium everolimus eluting PE Plus stent published in the American Journal of Cardiology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com